Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 29/07/2025

0.00 (0.00%)

Market capitalisation

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Thematics

thematic

Investment Companies

Hansa House View

thematic

Edison Growth Conference 2025

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free